Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study

Internal Medicine Journal
Guillaume Le GuennoB Godeau

Abstract

An increased risk of thrombosis has been reported in immune thrombocytopenic purpura (ITP), but the characteristics, risk factors of occurrence, recurrence and management of venous thromboembolic events (VTE) have been poorly investigated. To describe VTE and ITP characteristics, distribution of VTE risk factors and their impact on VTE features and recurrence. A retrospective study of patients with ITP and VTE registered in databases of three reference French centres of ITP. Among 49 patients, 66 VTE were recorded. The platelet count at the time of the first VTE was <100 × 109 /L for 28/43 (65%) patients. In total, 19/48 (40%) patients had at least one positive antiphospholipid test result. For the 10 VTE occurring in eight patients with platelet count <50 × 109 /L, ITP treatment was efficient in 7. One haemorrhagic complication associated with anticoagulant (AC) therapy was recorded. For 31/49 (63%) patients, long-term AC therapy could have been discussed after the first VTE, but only 13 received it. A second VTE occurred in 13 (27%) patients. The risk of recurrence was increased in patients with unprovoked VTE before ITP diagnosis or active cancer. VTE in ITP mainly occurred in the presence of multiple risk factors of TE. A l...Continue Reading

References

Sep 6, 2003·British Journal of Haematology·Annette J NeylonUNKNOWN Northern Region Haematology Group
Apr 22, 2004·Blood·Robert McMillan, Carol Durette
Jul 1, 2006·Journal of General Internal Medicine·Frederick A SpencerRobert J Goldberg
May 31, 2008·British Journal of Haematology·Carole Pierrot-Deseilligny DespujolBertrand Godeau
May 12, 2010·British Journal of Haematology·Willem M LijferingSuzanne C Cannegieter
Jul 24, 2010·International Journal of Hematology·Cheryl EngerAndrew T McAfee
Oct 20, 2010·British Journal of Haematology·Marianne T SeverinsenHenrik Toft Sørensen
May 11, 2012·British Journal of Haematology·Francesco Rodeghiero, Marco Ruggeri
Sep 11, 2012·Best Practice & Research. Clinical Haematology·Anne Flem Jacobsen, Per Morten Sandset
Oct 31, 2012·Journal of Thrombosis and Haemostasis : JTH·G OcakW M Lijfering
May 17, 2013·Seminars in Hematology·Axel Matzdorff, Juerg-Hans Beer
Jun 20, 2014·Journal of Thrombosis and Haemostasis : JTH·M RuggeriUNKNOWN Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311
Jun 17, 2015·Nature Reviews. Cardiology·John A Heit
Apr 21, 2018·American Journal of Hematology·Caroline MorbieuMatthieu Mahévas

❮ Previous
Next ❯

Citations

Aug 8, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Ankur JainD K Gupta
Jul 28, 2020·La Revue de médecine interne·M EbboB Godeau
Nov 24, 2019·Blood Reviews·Allyson M PishkoDouglas B Cines
Apr 7, 2021·British Journal of Haematology·Dawn SwanJecko Thachil
Dec 22, 2021·Hämostaseologie·Minna Voigtlaender, Florian Langer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.